Literature DB >> 6635442

In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus.

P Van der Auwera, J Klastersky.   

Abstract

The rapid emergence of strains resistant to rifampin suggests that for the treatment of bacterial infections rifampin should probably be combined with another antistaphylococcal drug. The authors examine the interaction of rifampin and oxacillin in various concentrations in vitro using a dynamic biophotometric technique. While synergism was observed occasionally, most concentrations studied exhibited either antagonism or indifference. No antagonism was observed with rifampin-resistant strains. Rifampin-resistant strains often emerged when the drug was tested alone. These findings again illustrate the complex and often unpredictable effect of combining rifampin with beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635442     DOI: 10.1093/clinids/5.supplement_3.s509

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

1.  Intracardiac device and prosthetic infections: What do we know?

Authors:  Lynn B Johnston; John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

2.  Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.

Authors:  A M Mackenzie; N E Macdonald
Journal:  Can J Infect Dis       Date:  1990

3.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

4.  Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.

Authors:  David J Riedel; Elizabeth Weekes; Graeme N Forrest
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 5.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.

Authors:  Guy Thwaites; Cressida Auckland; Gavin Barlow; Richard Cunningham; Gerry Davies; Jonathan Edgeworth; Julia Greig; Susan Hopkins; Dakshika Jeyaratnam; Neil Jenkins; Martin Llewelyn; Sarah Meisner; Emmanuel Nsutebu; Tim Planche; Robert C Read; Matthew Scarborough; Marta Soares; Robert Tilley; M Estée Török; John Williams; Peter Wilson; Sarah Wyllie; A Sarah Walker
Journal:  Trials       Date:  2012-12-18       Impact factor: 2.279

7.  In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.

Authors:  Christian Garzoni; Ilker Uçkay; Wilson Belaieff; Dominique Breilh; Domizio Suvà; Elzbieta Huggler; Daniel Lew; Pierre Hoffmeyer; Louis Bernard
Journal:  Springerplus       Date:  2014-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.